Stock AnalizHCA Healthcare, Inc. HCA
Hospital/Nursing Management · IPO 2011 · data as of November 13, 2026
HCA Healthcare, Inc. (HCA) is a healthcare company listed in the US with a market value of about $104.2B. In the twelve months to September 30, 2026 it had revenue of $78.7B and net income of $6.8B, a net margin of 8.6%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is value (5/5); the weakest is financial health (1/5).
Key numbers: a P/E of 16.6, a price to free cash flow of 17.5, 5-year revenue growth of 8% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% above the current price.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Checks not passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.7B | $75.6B | $70.6B | $65.0B | $60.2B | $58.8B | $51.5B | $51.3B | $46.7B | $43.6B | $41.5B |
| Net income | $6.8B | $6.8B | $5.8B | $5.2B | $5.6B | $7.0B | $3.8B | $3.5B | $3.8B | $2.2B | $2.9B |
| Free cash flow | $6.0B | $7.7B | $5.6B | $4.7B | $4.1B | $5.4B | $6.4B | $3.4B | $3.2B | $2.4B | $2.9B |
| EPS (diluted) | $30.14 | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
| Net margin | 8.6% | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | 5.1% | 7.0% |
| ROIC | — | 18.2% | 15.6% | 15.2% | 18.3% | 21.6% | 13.1% | 12.7% | 15.8% | 10.4% | 14.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 22 analysts is $483.41, 3% below the current price; targets range from $380.00 to $585.00; the consensus rating is “Buy”; expected EPS is $30.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is HCA Healthcare’s P/E ratio?
About 16.6, based on the last twelve months of diluted earnings per share (forward P/E about 15.9).
Is HCA Healthcare stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 3% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does HCA Healthcare pay a dividend?
Yes. The dividend yield is about 0.63%, and it has paid dividends for 8 years in our data.
Is HCA Healthcare a good stock to buy?
We do not give buy or sell advice. HCA Healthcare scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.